Loading
Latest filing published 18 Nov 2025 for Bioxytran, INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David Platt, listed as chief executive, appears in our data through filings on Bioxytran, Inc shares, published by SEC (Form 4). In total, 21 filings cover trades dated from 4 June 2021 to 25 October 2024.
Purchases make up the whole of the open-market record (1 purchase, €180k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 4 share grants.
The newest entry dates from 18 November 2025: a transaction, in Bioxytran, Inc. The latest purchase dates back some time: it was published 789 days ago, on 20 August 2024. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations